BioCentury | Feb 15, 2017
Distillery Therapeutics

Hematology

INDICATION: Immunodeficiency Mouse studies suggest transplant of engineered hematopoietic stem cells (HSCs) could help treat immunodeficiency. The HSCs consisted of HOXB4 -expressing mouse embryonic stem cell (ESC)-derived HSCs that had been co-cultured with a DLL1...
BioCentury | Aug 20, 2015
Distillery Therapeutics

Therapeutics: MicroRNA-196a (miR-196a); v-myc myelocytomatosis viral oncogene homolog (MYC; c-Myc); homeobox B7 (HOXB7)

...estrogen receptor-positive breast cancer patients previously treated with tamoxifen, high levels of both MYC and HOXB7...
...survival. In tamoxifen-resistant human breast cancer cell lines, knockdown or pharmacological inhibition of MYC decreased HOXB7...
...lymphoma (NHL). TARGET/MARKER/PATHWAY: MicroRNA-196a (miR-196a) ; v-myc myelocytomatosis viral oncogene homolog (MYC; c-Myc ); homeobox B7 (HOXB7...
BioCentury | Oct 27, 2014
Clinical News

Breast Cancer Index regulatory update

BioMerieux's Biotheranostics Inc. company said CMS posted a positive coverage and reimbursement policy for the Breast Cancer Index to determine the risk of early and late recurrence and benefit from extended endocrine therapy in patients...
BioCentury | Jul 28, 2014
Clinical News

Breast Cancer Index regulatory update

bioMerieux’s bioTheranostics Inc. company said the New York State Department of Health approved the company’s Breast Cancer Index (BCI) to determine the risk of early and late recurrence and benefit from extended endocrine therapy in...
BioCentury | Jul 28, 2014
Company News

bioMerieux sales and marketing update

bioMerieux’s bioTheranostics Inc. subsidiary said U.S. healthcare provider FedMed Inc. will cover genomic tests for patients with breast cancer and metastatic cancers. bioTheranostics said that FedMed has a preferred provider network that includes more than...
BioCentury | Sep 16, 2013
Clinical News

Breast Cancer Index diagnostic data

Researchers at Massachusetts General Hospital and colleagues reported data from 665 postmenopausal women with estrogen receptor-positive breast cancer in a prospective comparative study showing that only the BCI predicts risk for both early (0-5 years)...
BioCentury | Jun 30, 2011
Distillery Therapeutics

Indication: Cancer

...antagonizing HOXB7 might help treat tamoxifen-resistant breast cancer. Mice implanted with breast cancer cells expressing HOXB7...
...patients, higher levels of HOXB7 correlated with lower disease-free survival. Next steps could include identifying HOXB7...
BioCentury | Jan 5, 2009
Product Development

Intermediate decision-making

Oncotype DX from Genomic Health Inc. is used in over 50% of breast cancer patients to determine if they are at risk of recurrence and thus should receive chemotherapy following surgery. The problem is what...
BioCentury | Dec 22, 2008
Clinical News

Theros Breast Cancer Index: Data

Data from tissue samples from 166 estrogen receptor-positive breast cancer patients showed that Theros Breast Cancer Index (BCI) reduced the number of patients classified as having an intermediate risk of recurrence by 2.5-fold vs. Oncotype...
BioCentury | Jun 9, 2007
Clinical News

Downregulation of kinase linked to heritable CLL

...leukemia (CLL). A single nucleotide mutation was sufficient to increase the DNA-binding affinity of homeobox B7 (HOXB7...
Items per page:
1 - 10 of 13